Humana (NYSE:HUM) PT Lowered to $326.00 at UBS Group

Humana (NYSE:HUM) had its target price lowered by stock analysts at UBS Group from $334.00 to $326.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the insurance provider’s stock. UBS Group’s price target would suggest a potential upside of 5.32% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and dropped their price target for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. The Goldman Sachs Group dropped their price target on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Barclays dropped their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Argus lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Finally, Truist Financial restated a “hold” rating and set a $550.00 target price on shares of Humana in a research report on Friday, January 19th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $437.00.

Humana Stock Down 2.0 %

NYSE:HUM traded down $6.44 during mid-day trading on Thursday, hitting $309.54. The stock had a trading volume of 493,986 shares, compared to its average volume of 1,987,235. The stock has a 50-day simple moving average of $329.24 and a two-hundred day simple moving average of $396.94. The company has a market capitalization of $37.35 billion, a PE ratio of 15.60, a PEG ratio of 1.92 and a beta of 0.45. Humana has a twelve month low of $299.23 and a twelve month high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.38 earnings per share. On average, equities research analysts anticipate that Humana will post 16.06 EPS for the current year.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction on Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of HUM. Exchange Traded Concepts LLC lifted its holdings in Humana by 103.0% in the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after acquiring an additional 1,463 shares during the period. Caprock Group LLC raised its stake in shares of Humana by 3.6% during the 3rd quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock worth $693,000 after buying an additional 50 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Humana by 2.8% during the 3rd quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after buying an additional 22 shares during the last quarter. Czech National Bank raised its stake in shares of Humana by 46.4% during the 3rd quarter. Czech National Bank now owns 21,656 shares of the insurance provider’s stock worth $10,536,000 after buying an additional 6,866 shares during the last quarter. Finally, Aaron Wealth Advisors LLC acquired a new position in shares of Humana during the 3rd quarter worth $213,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.